The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation

European Journal of Human Genetics

Volumn 9, Issue 10, 2001, Pages 787-793

  Bergman, Annika ^a   Einbeigi, Zakaria ^a   Olofsson, Ulrica ^b   Taib, Ziad ^b   Wallgren, Arne ^a   Karlsson, Per ^a   Wahlström, Jan ^a   Martinsson, Tommy ^a   Nordling, Margareta ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

BRCA1 gene; Breast neoplasm; Founder effect; Haplotype; Ovarian neoplasm

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; MICROSATELLITE DNA;

AGE; ALLELE; ARTICLE; BREAST CANCER; CLINICAL OBSERVATION; CONTROLLED STUDY; FAMILIAL CANCER; FAMILY; FOUNDER EFFECT; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC CONSERVATION; GENETIC POLYMORPHISM; HAPLOTYPE; HETEROZYGOTE; HUMAN; OVARY CANCER; PHYLOGENY; PRIORITY JOURNAL; SWEDEN; TIME;

BRCA1 PROTEIN; BREAST NEOPLASMS; CONSERVED SEQUENCE; DNA MUTATIONAL ANALYSIS; FEMALE; FOUNDER EFFECT; GEOGRAPHY; HAPLOTYPES; HUMANS; MALE; MICROSATELLITE REPEATS; MUTAGENESIS, INSERTIONAL; MUTATION; PEDIGREE; SWEDEN; TIME FACTORS;

EID: 0034748570     PISSN: 10184813     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ejhg.5200704     Document Type: Article

References (30)

1. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
2. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13
3. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women
4. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families
5. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: Frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families
6. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes
7. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families
8. A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families
9. Evidence of a founder BRCA1 mutation in Scotland
10. New Austrian mutation in BRCA1 gene detected in three unrelated HBOC families
11. Analysis of BRCA1 and BRCA2 mutations in Hungarian families with breast or breast-ovarian cancer
12. Frequently occuring germ-line mutations of the BRCA1 gene in ovarian cancer families from Russia
13. Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden
14. Mutation analysis of the BRCA1 and BRCA2 genes in the Belgian patient population and identification of a Belgian founder mutation BRCA1 IVS5+3A > G
15. Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland
16. Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: Results of an international study
17. Modelling hereditary diseases using Galton-Watson processes
18. Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population
19. Mapping complex genetic traits in humans: New methods using a complete RFLP linkage map
20. Fine-scale genetic mapping based on linkage disequilibrium: Theory and applications
21. Likelihood analysis of disequilibrium mapping, and related problems
22. A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families
23. Parametric and nonparametric linkage analysis: A unified multipoint approach
24. New estimates of intergenerational time intervals for the calculation of age and origins of mutations
25. Fine mapping of the gene for carbohydrate-deficient glycoprotein syndrome, type I (CDG1): Linkage disequilibrium and founder effect in Scandinavian families
26. Psoriasis susceptibility locus in chromosome region 3q21 identified in patients from southwest Sweden
27. BRCA1 mutations and breast cancer in the general population: Analyses in women before age 35 years and in women before age 45 years with first-degree family history